Samsung Bioepis On The Secrets Of Its Success

Cost Leadership Just One Factor For Korean Biosimilars Specialist

Since being established in 2012, Samsung Bioepis has grown into a global biosimilars leader with one of the most robust portfolios of products and pipelines in the sector. Its executive vice-president talks about what is behind this rapid growth and the strategy the Samsung Group affiliate is pursuing to cope with the COVID-19 pandemic and become a fully integrated operation in the longer term.

Growth Strategy
Samsung Bioepis' Focus Remains On Biosimilars But Novel Biologics Are On The Long-Term Agenda • Source: Shutterstock

More from Biosimilars

More from Products